文献速递皮肤肿瘤

肿瘤浸润淋巴细胞评分改善II期黑色素瘤进展风险预测

Tumor-infiltrating lymphocyte scoring improves progression risk prediction in stage II melanoma: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2025-03-22

该回顾性队列研究纳入4家英国医院2004-2017年366例前哨淋巴结阴性的II期黑色素瘤患者,评估AJCC第八版亚分期与TIL评分的进展预测能力。

要点

  • 非活跃型TIL见于80%的进展肿瘤,提示高危。
  • TIL评分可在各亚分期内区分高低危,辅助识别可能获益于辅助免疫治疗者。

核心结论

  • AJCC第八版亚分期对II期黑色素瘤进展预测不佳,TIL评分可改善跨亚分期的风险分层。
  • TIL评分有望作为低成本方法更好识别可能从辅助免疫治疗获益的患者。

研究设计与样本

  • 回顾性队列研究,纳入4家英国医院2004-2017年前哨淋巴结阴性II期黑色素瘤患者366例,随访时间长。

主要发现

  • TIL评分独立预测进展风险:活跃型 vs 非活跃型 OR 0.298,P=.009;缺失型 vs 非活跃型 OR 0.436,P=.049。
  • 非活跃型TIL见于80%的进展肿瘤,提示高危。
  • TIL评分可在各亚分期内区分高低危:IIA期伴非活跃型TIL患者5年无进展生存与IIB/IIC期伴缺失/活跃型TIL患者相似。

临床怎么用

  • 在II期黑色素瘤风险分层中可考虑加入TIL评分,以弥补AJCC第八版亚分期的不足。
  • 对IIA期伴非活跃型TIL者可按高危管理,对IIB/IIC期伴缺失/活跃型TIL者需避免过度治疗。

局限性

  • 回顾性研究设计。
  • 研究结果的外部推广性未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American Joint Committee on Cancer eighth edition substaging might be suboptimal for predicting melanoma progression. Using it to select stage II patients for adjuvant immunotherapy risks overtreating low-risk stage IIB/IIC patients and undertreating high-risk stage IIA patients. Prognostic capability of tumor-infiltrating lymphocytes (TILs) is unclear in stage II melanoma. OBJECTIVE: To evaluate the American Joint Committee on Cancer eighth edition substaging and TIL scoring as predictors of progression in stage II melanoma. METHODS: Retrospective cohort study of 366 sentinel lymph node negative stage II melanoma patients from 4 UK hospitals (2004-2017), with long-term follow-up. RESULTS: Twenty-three percent of melanomas progressed (median 9.5-year follow-up). Among those, 41.5% were stage IIA, 41.5% IIB, and 17.1% IIC. TIL scoring independently predicted progression risk (brisk vs non-brisk: odds ratio: 0.298, P = .009; absent vs non-brisk: odds ratio: 0.436, P = .049) and progression-free survival. Nonbrisk TILs, present in 80% of progressing tumors, denoted high risk. TIL scoring split patients into high and low risk across substages: stage IIA patients with non-brisk TILs had similar 5-year progression-free survival to stage IIB/IIC patients with absent/brisk TILs. LIMITATIONS: Retrospective study design and unknown generalizability. CONCLUSION: Stage II melanoma progression is poorly predicted by the American Joint Committee on Cancer eighth edition substage. TIL scoring offers improved risk stratification across substages and could serve as a cost-effective method to better identify patients who may benefit from adjuvant immunotherapies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Adigbli G, Reed B, Khera B, et al. Tumor-infiltrating lymphocyte scoring improves progression risk prediction in stage II melanoma: A retrospective cohort study. J Am Acad Dermatol. 2025. PMID: 40122211. doi:10.1016/j.jaad.2025.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。